|
1
|
Bray F, Ren JS, Masuyer E and Ferlay J:
Global estimates of cancer prevalence for 27 sites in the adult
population in 2008. Int J Cancer. 132:1133–1145. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Estimated Cancer Incidence, Mortality and
Prevalence Worldwide in 2012. Globocan. 2012.http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx
|
|
3
|
Hannon GJ and Rossi JJ: Unlocking the
potential of the human genome with RNA interference. Nature.
431:371–378. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lee RC, Feinbaum RL and Ambros V: The
C. elegans heterochronic gene lin-4 encodes small RNAs with
antisense complementarity to lin-14. Cell. 75:843–854. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Filipowicz W, Bhattacharyya SN and
Sonenberg N: Mechanisms of post-transcriptional regulation by
microRNAs: Are the answers in sight? Nat Rev Genet. 9:102–114.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yang W, Lee DY and Ben-David Y: The roles
of microRNAs in tumorigenesis and angiogenesis. Int J Physiol
Pathophysiol Pharmacol. 3:140–155. 2011.PubMed/NCBI
|
|
8
|
Karaayvaz M, Zhang C, Liang S, Shroyer KR
and Ju J: Prognostic significance of miR-205 in endometrial cancer.
PloS One. 7:e351582012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Torres A, Torres K, Pesci A, Ceccaroni M,
Paszkowski T, Cassandrini P, Zamboni G and Maciejewski R:
Diagnostic and prognostic significance of miRNA signatures in
tissues and plasma of endometrioid endometrial carcinoma patients.
Int J Cancer. 132:1633–1645. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yu CC, Tsai LL, Wang ML, Yu CH, Lo WL,
Chang YC, Chiou GY, Chou MY and Chiou SH: mir145 targets the
SOX9/ADAM17 axis to inhibit tumor-initiating cells and
IL-6-mediated paracrine effects in head and neck cancer. Cancer
Res. 73:3425–3440. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nana-Sinkam P and Croce CM: MicroRNAs in
diagnosis and prognosis in cancer: What does the future hold?
Pharmacogenomics. 11:667–669. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ferracin M, Veronese A and Negrini M:
Micromarkers: miRNAs in cancer diagnosis and prognosis. Expert Rev
Mol Diagn. 10:297–308. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhou X, Wang Y, Shan B, Han J, Zhu H, Lv
Y, Fan X, Sang M, Liu XD and Liu W: The downregulation of
miR-200c/141 promotes ZEB1/2 expression and gastric cancer
progression. Med Oncol. 32:4282015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Toiyama Y, Hur K, Tanaka K, Inoue Y,
Kusunoki M, Boland CR and Goel A: Serum miR-200c is a novel
prognostic and metastasis-predictive biomarker in patients with
colorectal cancer. Ann Surg. 259:735–743. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tang H, Deng M, Tang Y and Xie X, Guo J,
Kong Y, Ye F, Su Q and Xie X: miR-200b and miR-200c as prognostic
factors and mediators of gastric cancer cell progression. Clin
Cancer Res. 19:5602–5612. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Valladares-Ayerbes M, Reboredo M,
Medina-Villaamil V, Iglesias-Díaz P, Lorenzo-Patiño MJ, Haz M,
Santamarina I, Blanco M, Fernández-Tajes J, Quindós M, et al:
Circulating miR-200c as a diagnostic and prognostic biomarker for
gastric cancer. J Transl Med. 10:1862012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Song F, Yang D, Liu B, Guo Y, Zheng H, Li
L, Wang T, Yu J, Zhao Y, Niu R, et al: Integrated microRNA network
analyses identify a poor-prognosis subtype of gastric cancer
characterized by the miR-200 family. Clin Cancer Res. 20:878–889.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gao YC and Wu J: MicroRNA-200c and
microRNA-141 as potential diagnostic and prognostic biomarkers for
ovarian cancer. Tumour Biol. 36:4843–4850. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cao Q, Lu K, Dai S, Hu Y and Fan W:
Clinicopathological and prognostic implications of the miR-200
family in patients with epithelial ovarian cancer. Int J Clin Exp
Pathol. 7:2392–2401. 2014.PubMed/NCBI
|
|
20
|
Marchini S, Cavalieri D, Fruscio R, Calura
E, Garavaglia D, Fuso Nerini IF, Mangioni C, Cattoretti G, Clivio
L, Beltrame L, et al: Association between miR-200c and the survival
of patients with stage I epithelial ovarian cancer: A retrospective
study of two independent tumour tissue collections. Lancet Oncol.
12:273–285. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Leskelä S, Leandro-García LJ, Mendiola M,
Barriuso J, Inglada-Pérez L, Muñoz I, Martínez-Delgado B, Redondo
A, de Santiago J, Robledo M, et al: The miR-200 family controls
beta-tubulin III expression and is associated with paclitaxel-based
treatment response and progression-free survival in ovarian cancer
patients. Endocr Relat Cancer. 18:85–95. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Vergho DC, Kneitz S, Kalogirou C, Burger
M, Krebs M, Rosenwald A, Spahn M, Löser A, Kocot A, Riedmiller H
and Kneitz B: Impact of miR-21, miR-126 and miR-221 as prognostic
factors of clear cell renal cell carcinoma with tumor thrombus of
the inferior vena cava. PloS One. 9:e1098772014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wotschofsky Z, Busch J, Jung M,
Kempkensteffen C, Weikert S, Schaser KD, Melcher I, Kilic E, Miller
K, Kristiansen G, et al: Diagnostic and prognostic potential of
differentially expressed miRNAs between metastatic and
non-metastatic renal cell carcinoma at the time of nephrectomy.
Clin Chim Acta. 416:5–10. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Butz H, Szabó PM, Khella HW, Nofech-Mozes
R, Patocs A and Yousef GM: miRNA-target network reveals miR-124 as
a key miRNA contributing to clear cell renal cell carcinoma
aggressive behaviour by targeting CAV1 and FLOT1. Oncotarget.
6:12543–12557. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tuomarila M, Luostari K, Soini Y, Kataja
V, Kosma VM and Mannermaa A: Overexpression of microRNA-200c
predicts poor outcome in patients with PR-negative breast cancer.
PloS One. 9:e1095082014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Madhavan D, Zucknick M, Wallwiener M, Cuk
K, Modugno C, Scharpff M, Schott S, Heil J, Turchinovich A, Yang R,
et al: Circulating miRNAs as surrogate markers for circulating
tumor cells and prognostic markers in metastatic breast cancer.
Clin Cancer Res. 18:5972–5982. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Antolín S, Calvo L, Blanco-Calvo M,
Santiago MP, Lorenzo-Patiño MJ, Haz-Conde M, Santamarina I,
Figueroa A, Antón-Aparicio LM and Valladares-Ayerbes M: Circulating
miR-200c and miR-141 and outcomes in patients with breast cancer.
BMC Cancer. 15:2972015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Song C, Liu LZ, Pei XQ, Liu X, Yang L, Ye
F and Xie X, Chen J, Tang H and Xie X: miR-200c inhibits breast
cancer proliferation by targeting KRAS. Oncotarget. 6:34968–34978.
2015.PubMed/NCBI
|
|
29
|
Diaz T, Tejero R, Moreno I, Ferrer G,
Cordeiro A, Artells R, Navarro A, Hernandez R, Tapia G and Monzo M:
Role of miR-200 family members in survival of colorectal cancer
patients treated with fluoropyrimidines. J Surg Oncol. 109:676–683.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tejero R, Navarro A, Campayo M, Viñolas N,
Marrades RM, Cordeiro A, Ruíz-Martínez M, Santasusagna S, Molins L,
Ramirez J and Monzó M: miR-141 and miR-200c as markers of overall
survival in early stage non-small cell lung cancer adenocarcinoma.
PloS One. 9:e1018992014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li J, Li X, Ren S, Chen X, Zhang Y, Zhou
F, Zhao M, Zhao C, Chen X, Cheng N, et al: miR-200c overexpression
is associated with better efficacy of EGFR-TKIs in non-small cell
lung cancer patients with EGFR wild-type. Oncotarget. 5:7902–7916.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kim MK, Jung SB, Kim JS, Roh MS, Lee JH,
Lee EH and Lee HW: Expression of microRNA miR-126 and miR-200c is
associated with prognosis in patients with non-small cell lung
cancer. Virchows Arch. 465:463–471. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Berghmans T, Ameye L, Willems L, Paesmans
M, Mascaux C, Lafitte JJ, Meert AP, Scherpereel A, Cortot AB,
Cstoth I, et al: Identification of microRNA-based signatures for
response and survival for non-small cell lung cancer treated with
cisplatin-vinorelbine A ELCWP prospective study. Lung Cancer.
82:340–345. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liu XG, Zhu WY, Huang YY, Ma LN, Zhou SQ,
Wang YK, Zeng F, Zhou JH and Zhang YK: High expression of serum
miR-21 and tumor miR-200c associated with poor prognosis in
patients with lung cancer. Med Oncol. 29:618–626. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhao J, Zhao Y, Wang Z, Xuan Y, Luo Y and
Jiao W: Loss expression of micro ribonucleic acid (miRNA)-200c
induces adverse post-surgical prognosis of advanced stage non-small
cell lung carcinoma and its potential relationship with ETAR
messenger RNA. Thorac Cancer. 6:421–426. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lin HM, Castillo L, Mahon KL, Chiam K, Lee
BY, Nguyen Q, Boyer MJ, Stockler MR, Pavlakis N, Marx G, et al:
Circulating microRNAs are associated with docetaxel chemotherapy
outcome in castration-resistant prostate cancer. Br J Cancer.
110:2462–2471. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yu H, Duan B, Jiang L, Lin M, Sheng H,
Huang J and Gao H: Serum miR-200c and clinical outcome of patients
with advanced esophageal squamous cancer receiving platinum-based
chemotherapy. Am J Transl Res. 6:71–77. 2013.PubMed/NCBI
|
|
38
|
Tanaka K, Miyata H, Yamasaki M, Sugimura
K, Takahashi T, Kurokawa Y, Nakajima K, Takiguchi S, Mori M and
Doki Y: Circulating miR-200c levels significantly predict response
to chemotherapy and prognosis of patients undergoing neoadjuvant
chemotherapy for esophageal cancer. Ann Surg Oncol. 20(Suppl 3):
S607–S615. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hamano R, Miyata H, Yamasaki M, Kurokawa
Y, Hara J, Moon JH, Nakajima K, Takiguchi S, Fujiwara Y, Mori M and
Doki Y: Overexpression of miR-200c induces chemoresistance in
esophageal cancers mediated through activation of the Akt signaling
pathway. Clin Cancer Res. 17:3029–3038. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Berglund M, Hedström G, Amini RM, Enblad G
and Thunberg U: High expression of microRNA-200c predicts poor
clinical outcome in diffuse large B-cell lymphoma. Oncol Rep.
29:720–724. 2013.PubMed/NCBI
|
|
41
|
Wszolek MF, Rieger-Christ KM, Kenney PA,
Gould JJ, Silva Neto B, Lavoie AK, Logvinenko T, Libertino JA and
Summerhayes IC: A MicroRNA expression profile defining the invasive
bladder tumor phenotype. Urol Oncol. 29:794–801, e1. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wiklund ED, Bramsen JB, Hulf T, Dyrskjøt
L, Ramanathan R, Hansen TB, Villadsen SB, Gao S, Ostenfeld MS,
Borre M, et al: Coordinated epigenetic repression of the miR-200
family and miR-205 in invasive bladder cancer. Int J Cancer.
128:1327–1334. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Yu J, Ohuchida K, Mizumoto K, Sato N,
Kayashima T, Fujita H, Nakata K and Tanaka M: MicroRNA,
hsa-miR-200c, is an independent prognostic factor in pancreatic
cancer and its upregulation inhibits pancreatic cancer invasion but
increases cell proliferation. Mol Cancer. 9:1692010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Moher D, Liberati A, Tetzlaff J and Altman
DG: PRISMA Group. Preferred reporting items for systematic reviews
and meta-analyses: The PRISMA statement. J Clin Epidemiol.
62:1006–1012. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Tierney JF, Stewart LA, Ghersi D, Burdett
S and Sydes MR: Practical methods for incorporating summary
time-to-event data into meta-analysis. Trials. 8:162007. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
DerSimonian R and Laird N: Meta-analysis
in clinical trials. Control Clin Trials. 7:177–188. 1986.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Guarino M, Rubino B and Ballabio G: The
role of epithelial-mesenchymal transition in cancer pathology.
Pathology. 39:305–318. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Gregory PA, Bert AG, Paterson EL, Barry
SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y and Goodall GJ:
The miR-200 family and miR-205 regulate epithelial to mesenchymal
transition by targeting ZEB1 and SIP1. Nat Cell Biol. 10:593–601.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Liu H, Brannon AR, Reddy AR, Alexe G,
Seiler MW, Arreola A, Oza JH, Yao M, Juan D, Liou LS, et al:
Identifying mRNA targets of microRNA dysregulated in cancer: With
application to clear cell renal cell carcinoma. BMC Syst Biol.
4:512010. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Vilming Elgaaen B, Olstad OK, Haug KB,
Brusletto B, Sandvik L, Staff AC, Gautvik KM and Davidson B: Global
miRNA expression analysis of serous and clear cell ovarian
carcinomas identifies differentially expressed miRNAs including
miR-200c-3p as a prognostic marker. BMC Cancer. 14:802014.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Yeh TS, Wang F, Chen TC, Yeh CN, Yu MC,
Jan YY and Chen MF: Expression profile of microRNA-200 family in
hepatocellular carcinoma with bile duct tumor thrombus. Ann Surg.
259:346–354. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Blanco-Calvo M, Tarrío N, Reboredo M,
Haz-Conde M, García J, Quindós M, Figueroa A, Antón-Aparicio L,
Calvo L and Valladares-Ayerbes M: Circulating levels of GDF15, MMP7
and miR-200c as a poor prognostic signature in gastric cancer.
Future Oncol. 10:1187–1202. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Hayes DF, Isaacs C and Stearns V:
Prognostic factors in breast cancer: Current and new predictors of
metastasis. J Mammary Gland Biol Neoplasia. 6:375–392. 2001.
View Article : Google Scholar : PubMed/NCBI
|
